Safety and efficacy of recombinant alpha1-antitrypsin therapy in cystic fibrosis

Pediatric Pulmonology

Volumn 41, Issue 2, 2006, Pages 177-183

  Martin, S Lorraine ^a   Downey, Damian ^b   Bilton, Diana ^c   Keogan, Mary T ^c   Edgar, Julia ^d   Elborn, J Stuart ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

^c PAPWORTH HOSPITAL   (United Kingdom)

^d PPL Therapeutics   (United Kingdom)

Author keywords

Alpha1 antitrypsin; Cystic fibrosis; Inflammation; Neutrophil elastase

Indexed keywords

ALPHA 1 ANTITRYPSIN; INTERLEUKIN 8; LEUKOCYTE ELASTASE; MYELOPEROXIDASE; PLACEBO; PROTEINASE; TUMOR NECROSIS FACTOR RECEPTOR;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE MARKER; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; HUMAN; LUNG FIBROSIS; MALE; NEBULIZATION; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPUTUM ANALYSIS;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ALPHA 1-ANTITRYPSIN; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY FLOW RATES; HUMANS; LEUKOCYTE ELASTASE; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PILOT PROJECTS; RECOMBINANT PROTEINS; SERINE PROTEINASE INHIBITORS; SPUTUM; TREATMENT OUTCOME;

EID: 31544470902     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.20345     Document Type: Article

References (29)

1. Konstan MW, Berger M. Infection and inflammation of the lung in cystic fibrosis. In: Davis PB, editor. Cystic fibrosis. New York: Dekker; 1993. p 219-275.
2. Bruce MC, Poncz L, Klinger JD, Stern RC, Tomashefski JR, Dearborn DG. Biochemical and pathological evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am Rev Respir Dis 1985;132:529-535.
3. Birrer P, McElvaney NG, Rudeberg A, Sommer CW, Liechti-Gallati S, Kraemer R, Hubbard R, Crystal RG. Protease-antiproteaseimbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 1994;150:207-213.
4. Tosi MF, Zakem H, Berger M. Neutrophil elastase cleaves C3bi on opsonized Pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest 1990;86:300-308.
5. Döring G, Knight R, Bellon G. Immunology of cystic fibrosis. In: Hodson ME, Geddes D, editors. Cystic fibrosis. Kluwer Academic Publishers, Norwell, MA, USA (Chapman and Hall; 1994).
6. Schuster A, Fahy JV, Ueki I, Nadel JA. Cystic fibrosis sputum induces a secretory response from airway gland serous cells that can be prevented by neutrophil protease inhibitors. Eur Respir J 1995;8:10-14.
7. 1- anti-trypsin for the treatment of cystic fibrosis. Chest 1996;110:256-260.
8. 1-anti-trypsin treatment for cystic fibrosis. Lancet 1991;337:392-394.
9. Tebbutt SJ. Technology evaluation: transgenic α-1-antitrypsin (AAT), PPL Therapeutics. Curr Opin Mol Ther 2000;2:199-204.
10. Martin SL, Lynas JF, Walker B, Elborn JS. Improved protease inhibition for storage and analysis of CF sputum. Pediatr Pulmonol 1998;26:382-383.
11. Castillo MJ, Nakajima K, Zimmerman M, Powers JC. Sensitive substrates for human leukocyte and porcine pancreatic elastase: a study of the merits of various chromophoric and fluorogenic leaving groups in assays for serine proteases. Anal Biochem 1979;99:53-64.
12. Hendry J, Elborn JS, Nixon L, Shale DJ, Webb AK. Cystic fibrosis: inflammatory response to infection with Burkholderia cepacia and Pseudomonas aeruginosa. Eur Respir J 1999;14:435-438.
13. Jones AM, Martin SL, Bright-Thomas RJ, Dodd ME, McDowell A, Moffitt KL, Elborn JS, Webb AK. Inflammatory changes in cystic fibrosis patients with transmissible Pseudomonas aeruginosa. Eur Respir J 2003;22:503-506.
14. Barbara JAJ, Smith WB, Gamble JR, Vanostade X, Vandenabeele P, Tavernier J, Fiers W, Vadas MA, Lopez AF. Dissociation of TNF-α cytotoxic and proinflammatory activities by P55 receptor-selective and P75 receptor-selective TNF-α mutants. EMBO J 1994;13:843-850.
15. Goldstein W, Döring G. Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis. Am Rev Respir Dis 1986;134:49-56.
16. Suri R, Marshall LJ, Wallis C, Metcalfe C, Shute JK, Bush A. Safety and use of sputum induction in children with cystic fibrosis. Pediatr Pulmonol 2003;35:309-313.
17. Ordoñez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF, Daines CL, Gibson RL, McNamara S, Retsch-Bogart GZ, Zeitlin PL, Aitken ML. Inflammatory and microbiological markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 2003;168:1471-1475.
18. 1- protease inhibitors in normal volunteers. Am J Respir Crit Care Med 1997;155:536-541.
19. Chughtai B, O'Riordan TG. Potential role of inhibitors of neutrophil elastase in treating diseases of the airway. J Aerosol Med 2004;17:289-298.
20. 1-proteinase inhibitor: further evidence for methionine at the active centre. J Biol Chem 1979;254:4022-4026.
21. 1-proteinase inhibitor by activated human neutrophils. Respir Med 2004;98:865-871.
22. 1-protease inhibitor: implications for the pathogenesis of cystic fibrosis lung disease. Infect Immun 1999;67:1207-1212.
23. 1-antitrypsin in cystic fibrosis bronchopulmonary secretions. Pediatr Pulmonol 1989;7:12-17.
24. 1-proteinase inhibitor by selective bacterial proteinases. Biol Chem 1999;380:1211-1216.
25. Gipson TS, Bless NM, Shanley TP, Crouch LD, Bleavins MR, Younkin EM, Sarma V, Gibbs DF, Tefera W, McConnell PC, Mueller WT, Johnson KJ, Ward PA. Regulatory effects of endogeneous protease inhibitors in acute lung injury. J Immunol 1999;162:3653-3662.
26. Zani ML, Nobar SM, Lacour SA, Lemoine S, Boudier C, Bieth JG, Moreau T. Kinetics of the inhibition of neutrophil proteinases by recombinant elafin and pre-elafin (trappin-2) expressed in Pichia pastoris. Eur J Biochem 2004;271:2370-2378.
27. Simpson AJ, Maxwell AI, Govan JRW, Haslett C, Sallenave JM. Elafin (elastase-specific inhibitor) has anti-microbial activity against Gram-positive and Gram-negative respiratory pathogens. FEBS Lett 1999;452:309-313.
28. Vogelmeier C, Gillissen A, Buhl R. Use of secretary leukoprotease inhibitor to augment lung antineutrophil activity. Chest 1996;110:261-266.
29. McElvaney NG, Doujaiji B, Moan MJ, Burnham MR, Wu MC, Crystal RG. Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolised to normals and individuals with cystic fibrosis. Am Rev Respir Dis 1993;148:1056-1060.